• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Journal of Neuroimmunology

    Journal of Neuroimmunology

    JournalISSN 0165-5728eISSN 1872-8421中科院 医学 4区

    年发文量

    研究主题

    论文(15140)

    排序
    1Inpatient Administration of Complement Inhibitors As Rapid-Acting Therapy for Recurrent or Refractory Myasthenic Exacerbation: A Case Series, Review of the Literature, and Discussion of Pathophysiology
    Julia Greenberg, Muhannad Seyam,Srikanth Muppidi

    Background Complement inhibitors are primarily used for symptomatic/refractory but stable myasthenic patients in the outpatient setting, however there is emerging data to suggest that complement inhibitors may be an effective rescue therapy in acute myasthenic exacerbation or crisis. Methods We present two cases of non-ventilator-dependent patients with refractory or recurrent myasthenic exacerbation in whom eculizumab was used as a rescue therapy, review the literature to date on inpatient use of complement inhibitor therapy for myasthenic crisis/exacerbation, and discuss the pathophysiology underlying rapid clinical response. Results Both patients had a rapid response to eculizumab with return of ability to speak and swallow within 48 h in one patient and reduction in MG-ADL score of >6 points within 2 weeks in one patient. Both achieved minimal symptom expression (defined as MG-ADL score of 0 or 1) within weeks and had sustained response to outpatient complement inhibitor therapy. Nineteen previously published papers (58 patients) were identified. Many patients had a clinically significant reduction in MG-ADL score or other objective evidence of clinical improvement within days, and had a sustained benefit with continued outpatient therapy. Conclusions Our findings add to a growing body of literature suggesting that complement inhibition may be a useful, fast-acting therapy for myasthenic exacerbation in the inpatient setting in some cases. This rapid response is likely due to functional complement blockade in patients with complement mediated neuromuscular junction damage as a primary cause of MG exacerbation/crisis.

    2027
    引用
    AI阅读
    加入学术空间
    2Critical Advances and Translational Bottlenecks of Gut Microbiota-Gut-brain Axis Targeted Therapy for Neurodegenerative and Neurodevelopmental Disorders
    Xinyi Yu, Junrong He,Mei Liu
    2027
    引用
    AI阅读
    加入学术空间
    3Anti-neuronal Cell-Surface Antibodies in Patients Diagnosed with Parkinson-like Disorders
    Yoya Ono,Akio Kimura,Akira Takekoshi,Yasuko Mori,Nobuaki Yoshikura, Takenobu Murakami, Akihiro Kotani,Yoshikazu Uesaka,Hiroaki Yaguchi,Ichiro Yabe,Keiko Tanaka,Takayoshi Shimohata

    Background Some patients with autoimmune encephalitis with anti-neuronal antibodies exhibit symptoms that resemble Parkinson-like disorders (an alternative term for atypical Parkinsonism) including progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). Of the anti-neuronal antibodies, anti-neuronal cell-surface antibodies (NSAbs) are typically associated with a direct pathogenic role. In this study, we aimed to evaluate NSAbs in patients diagnosed with Parkinson-like disorders and characterize the clinical features of NSAb-positive patients. Methods We included 135 patients: 48 with PSP, 45 with CBS, and 42 with MSA. Clinical features were defined by the Movement Disorder Society PSP criteria, Armstrong criteria, and Movement Disorder Society MSA criteria, respectively. These patients were referred for antibody testing because of atypical clinical features or a suspected autoimmune etiology. We screened NSAbs in the cerebrospinal fluid of these patients using tissue-based assays on frozen rat brain sections and immunocytochemistry on rat hippocampal live neuronal cell cultures. For patients with positive findings, we examined NSAbs using cell-based assays. Results In two patients diagnosed with clinically probable MSA-cerebellar type, the presence of NSAbs was suggested by tissue-based assays and immunocytochemistry. Further analysis identified the target antigens of these NSAbs as seizure-related 6 homolog like 2 (Sez6l2) and metabotropic glutamate receptor 5 (mGluR5). Conclusions Our results suggest that some patients with clinical features of MSA may rarely have NSAbs associated with autoimmune encephalitis, including anti-Sez6l2 and anti-mGluR5 antibodies, potentially expanding the spectrum of autoimmune encephalitis that can mimic MSA.

    2027
    引用
    AI阅读
    加入学术空间
    4Urolithin A Ameliorates Experimental Autoimmune Myasthenia Gravisin Association with Mitochondrial Quality Control–related and Inflammasome Signaling Changes
    Nan Zhang,Xiaotong Kong, Shihua Yu,Shanshan Peng,Guanghao Xin,Fanfan Xu, Yingying Geng, Guangzhao Zhu,Huixue Zhang,Lihua Wang
    2027
    引用
    AI阅读
    加入学术空间
    5Diagnoses Associated with Elevated Angiotensin-Converting Enzyme in Cerebrospinal Fluid
    Athena Dao, Andrew Liang, Ryan Walsh
    2027
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 15140 篇论文

    高被引作者

    作者引用发文
    Howard L. Weiner425987
    Cedric S. Raine4175111
    Hans Lassmann398297
    Hans Link393270
    Tomas Olsson3791118
    Hans-Peter Hartung341782
    Francesca Aloisi336241
    Josep Dalmau Obrador306735
    Michael K. Racke289061
    Jack P Antel288376

    高产作者

    作者引用发文
    Tomas Olsson3791118
    Cedric S. Raine4175111
    Angela Vincent1903104
    Hans Lassmann398297
    Howard L. Weiner425987
    Hans-Peter Hartung341782
    Gianvito Martino127381
    Jack P Antel288376
    Hans Link393270
    Comi Giancarlo129362

    相关期刊

    Reviews in the neurosciences
    Journal of NeuroVirology
    Journal of neuroinflammation
    Neurotherapeutics
    CNS Neuroscience & Therapeutics
    Annals of clinical and translational neurology
    Neuroimmunology and Neuroinflammation
    Nature Reviews Neurology
    Journal of NeuroImmune Pharmacology
    Neurology: Neuroimmunology & Neuroinflammation